FLT3 and acute myeloid leukemia: We performed a preliminary ex vivo experiment to evaluate the therapeutic effect of the triple combination on primary AML specimens (clinical profiles of patients available in Table 1), including bone marrow (BM) mononuclear cells (BMMNCs) from FLT3-mut AML patients (newly diagnosed shown in Figure 6A–C; Patient 6 in Supplementary Figure S2A; refractory shown in Figure 6D,E; Patient 7 in Supplementary Figure S2B).